An Innovative Ferroptosis-related Genes Signature for Prediction of Prognosis and Immune Microenvironment in Patients with Hepatocellular Carcinoma
Shihang Zhang,Jian Xu,Jianguo Wang,Bingbing Shen,Jianxin Jiang
DOI: https://doi.org/10.21203/rs.3.rs-2315131/v1
2022-01-01
Abstract:Abstract Background: Hepatocellular carcinoma (HCC) is a lethal malignancy with high heterogeneity, which impedes prognostic prediction. Cuproptosis is an innovative copper-trigged modality of mitochondrial cell death. Ferroptosis is a unique form of programmed cell death with iron-dependent phospholipid peroxidation. The target of this study was to establish a new signature with ferroptosis-related genes conjoining cuproptosis-related genes for the prediction of prognosis and tumor immunity in patients with HCC. Method: The expression profiles and corresponding clinical data of HCC patients were retrieved from TCGA. Pearson correlation analysis was conducted to identify the cuproptosis-related ferroptosis genes (CRFGs). A risk prognostic signature of 5-gene was constructed based on the CRFGs via the Cox regression and the least absolute shrinkage and selection operator (LASSO) method. Subsequently, the prognostic performance of the signature was evaluated by survival analysis, nomogram, Cox regression, clinicopathological characteristics correlation analysis, and the receiver operating characteristic (ROC) curve. Furthermore, the GO, KEGG pathway, GSEA, protein-protein interaction (PPI), the correlation between the signature risk score and immune cell infiltration, immune checkpoint, immune function, TMB, TIDE score, ESTIMATE score, and anticancer drug sensitivity were analyzed. Results: The 5-CRFGs signature comprising ATG13, BAP1, ELAVL1, SLC38A1, and YY1AP1 were explored to ameliorate the prognosis prediction of HCC patients. Kaplan-Meier analysis and ROC curve revealed the high-risk group associated with a poorer prognosis compared to the low-risk group. Cox regression and stratified survival analysis demonstrated that this signature was a risk factor independent of various clinical parameters. Moreover, immune cell infiltration, immune function, immune checkpoint, increased TMB, decreased TIDE score, ESTIMATE score, and half-inhibitory concentration significantly differed between high-and low-risk subtypes, which implied that the signature had acceptable assessing potency in the clinical efficacy of chemotherapy and immunotherapy. Conclusion: The novel cuproptosis-related ferroptosis gene signature indicated extraordinary predictive potency in prognosis and the immune microenvironment, which can provide a potentially promising therapeutic strategy for HCC patients.